Learn to relax, lose weight, feel amazing!! A practical multimedia guide from beginner all the way to advanced levels all in one program. Based on authentic traditional teachings from the head disciple of a Grandmaster of Taoist and Buddhist healing arts.
Leaky Gut Syndrome is the one condition that is responsible for a multitude of debilitating diseases. Understanding this common condition is the key to total health and wellbeing. Read how I keep MS condition totally under control.
A Science based alternative/natural approach to treating Adhd, drug addictions, and other health conditions. Dr. C E Gant has over 30 years experience in Alternative and Integrative medicine. Get real solutions for healing without drugs.
The 30 Days to Wellness Program can help you get lean and healthy even if you have carried too much body weight for too long. You can do it with the 30 Days to Wellness program and the support provided by the Liberation Wellness team.
This is a rose gardening book that provides a guide to growing a healthy and beautiful rose garden. It provides information regarding common problems encountered whilst trying to grow roses and how to get the most out of your rose garden
Awesome Converting Natural Health Product With 75% Payout - Help People Stop Getting Sick and Feel Great! Great Sales Video and Content Affiliates find out how to cash in here: http://www.7AncientHealthSecrets.com/affiliate.htm l
New E-book on the secrets and information on how to maximize your finches well being and health levels. Breeding your finch and making money.
Learn how to play golf really well in 7 days. This is an eBook and MP3 audio that would appeal to all levels of golfers. The commission is 60% on the $39.95 price. Affiliate Resources at: http://howtogolfreallywell.com/affiliate-resources
In the area of application development, Energy Makeover Services is aspiring to provide useful software applications to holistic health practitioners. As practitioners, we are well aware of this largely untapped market and the need to fill this void.
A Book Devoted Purely For Budget Travel And Discount Travel. All The Travel Hot Spots, The Unknown Secrets, The Special Deals.
Controversial diet and lifestylebook, celebrity endorsed and features expert from Oprah Winfrey, high commision of 35% and bestselling product in Scandinavia, now in the Us!
High Conversion Sales Copy! 70% Commission on $33.00!! Comprehensive Guide to Swine Flu including its history, how it kills, and how to treat and/or survive the virus as well as additional health information to treat and prevent the infection naturally.
What may be a new outermost layer of the Earth's core has been found, geoscientists have revealed.
This discovery could help solve mysteries of the planet's magnetic field, researchers say.
The Earth's core is composed mainly of iron, divided into a solid inner center roughly 1,500 miles (2,440 kilometers) wide covered by a liquid outer layer about 1,400 miles (2,250 km) thick. Even though the bulk of the core is iron, researchers also knew it contained a small amount of lighter elements such as oxygen and sulfur. As the inner core crystallized over time, scientists think this process forced out most of these light elements, which then migrated through the liquid outer core.
Now geoscientists think they have detected all these light elements concentrated in the outermost parts of the core.
"Ever since core structure started to be studied, there were hints of structure there — that's why we looked for it," said researcher George Helffrich, a geologist and seismologist at the University of Bristol in England.
Seismic speed changes
To investigate the core, researchers monitored seismic waves that traveled through its outer layer. The waves were generated by earthquakes in South America and the southwestern Pacific Ocean, and were recorded using arrays of seismometers in Japan and northern Europe.
The speeds at which seismic waves traveled through the outer core at different depths suggest that its composition does not remain the same all the way through. Instead, the uppermost 185 miles (300 km) or so is a distinct structure, with the section nearest the boundary consisting up to 5 percent by weight of light elements.
"The seismic structure we found is hard to deny — the signal is obvious to the eye in the data that we used," Helffrich told OurAmazingPlanet.
While Helffrich would not call their discovery a new layer of the core, he noted that "others might." He likened the potential new layer to the layers of the atmosphere.
"Think about the stratosphere above your head — is it a layer? There's no boundary to it, only a change in the temperature profile with altitude," Helffrich said. "Similarly, there's no boundary we infer inside the top of the core, just a slow droop in wave speed and then, possibly, a slight increase as you approach the core's surface."
Maintaining the magnetic field
These findings could help solve mysteries regarding the Earth's magnetic field.
"One enduring problem is how to power it for the 3 billion years, for which it seems to have been running," Helffrich said. The spinning of the Earth's core is thought to power the magnetic field that surrounds the planet.
The most plausible solution, Helffrich explained, is that expulsion of light elements from the inner core liberated what is called gravitational potential energy. As this lighter liquid rose upward, it imparted energy downward that drove the flow of metal in the core, which in turn helped keep the magnetic field running. "That fits with the wave speed profile that we observe," Helffrich said.
Future earthquakes might provide even better looks at this outermost structure. "New seismic networks in, say, China, India or the U.S. might provide even larger datasets too," Helffrich said. "I suspect that the main improvement to the work will be to model core liquids better and to balance the growth of the inner core with the composition of the layer."
Helffrich and his colleague, geophysicist Satoshi Kaneshima at the University of Kyushu in Japan, detailed their findings in the Dec. 9 issue of the journal Nature.
This article was provided by OurAmazingPlanet, a sister site of LiveScience.
Promote our book to people sitting at their computers who suffer from back pain, Carpel Tunnel, and bad circulation. A book of exercises and stretches that can be done at your desk. High commissions, and great product.
Make Tons Of Money Today By Promoting The Newest Revolutionary Diet And Body Sculpting Sysytem/education On The Market Formulated From The Latest Research. By Choosing To Partner Today You Not Only Stand By Health Awareness But Merely A Way Of Life!!!
We Enable Our Members And Guests To Clarify Their Lives And Goals And Create Health, Harmony And Happiness As Well As Growth.
Offering 70% commissions on this unique information product that helps with a variety of health problems. Sells for $47 with a $17 upsell. Creating funnels for different health niches.
National Institute for health and clinical excellence (NICE) will recommend from Roche-AVASTIN (bevacizumab) when used in combination with taxane as a useful, cost-effective treatment option for people with breast cancer that has spread. Health care cost storage envelope body which offer the drug "limited and existing treatments compared with uncertain benefits for patients."
Roche has calculated that the average total cost of treating a patient with AVASTIN plus chemotherapy exceeds $52,000, according to Reuters.
"Unfortunately, we have not received to show no evidence of the manufacturer, bevacizumab can significantly extend a patient life or, more importantly, offer a better quality of life than existing treatments," NICE Managing Director Andrew Dillon says in a statement. "Although the data show to be seemed that the drug can slow down the growth and spread of cancer, varies the size of this effect between studies." "Furthermore, it was extremely clear that the benefits in terms of slowing tumor growth in overall survival benefits that is something really important for the patients translated."
He adds that the body is consciously the FDA and EMEA review license of the drug for the treatment of metastatic breast cancer are. "If either... changes announce your licensing decision affecting our advice to the NHS, we change it accordingly," he warns.
The decision is no big surprise as Reuters notes, since AVASTIN has already been rejected for colorectal cancer. But the negative comments are mark uncertainty about its use elsewhere.
Monday's Bloomberg reported AVASTIN could not survive in a study of patients with brain cancer diagnosed to extend. Patients given living brain cancer drug Avastin with radiation therapy and Merck's Temodar 19.6 months, depending on according to the results of the study in the journal of Clinical Oncology. This figure compares life 21.1 months in patients with the extension only the other two treatments in another study given.
-NICE statement to get
-Schauen you are Reuters reporting
Reading you the Bloomberg report
Related articles:
Roche-AVASTIN rejected by NICE for colorectal cancer
AVASTIN, Tamiflu Roche depress sales by 7 %
Europe connects breast cancer check AVASTIN
Roche-AVASTIN receives FDA Aufschub--now
New! Save time, reduce stress and make the most of the season with a complete plan. Prepare for practices in 5 minutes. 3 bonuses including a certificate maker. Certificate maker also offered for soccer, baseball, cheerleading and volleyball. Brilliant!
Top Colon Cleanse and Detox Solution, Cleansing your Colon For Health *amazing Conversions* The Latest Affiliate tools here: www.colon-cleanse-for-health.com/affiliate.html
Everything about dental health and disease. Includes where disease comes from how to prevent it how to treat it. How to save money. Includes info on dental specialists, when you need them, and how to use them. Great info on dental insurance!
Golden Retriever Dog Book on choosing, caring for and training your Golden Retriever. Golden Retriever puppy training and obedience training as well as grooming and health care. Owners Manual. Ebooks / Audio / Visual package.
Workout Without Working Out -- Subliminal Health & Fitness Videos See http://www.subliminalhealthfitness.com/shf_affilia tes.htm
Dr. Miglioretti and her co-authors are working on an issue at the heart of recent controversies about breast cancer screening mammograms. In November 2009, new recommendations—including that women should discuss with their doctors whether to begin having regular screening mammograms at age 40 or wait till age 50—were issued by the U.S. Preventive Services Task Force, an independent panel of health care providers who generate medical guidelines based on clinical research.
Some facts related to the new recommendations prompted the study by Dr. Miglioretti and colleagues:
Mammography can detect cancer in women in their 40s.
But these women are at higher risk than are older women for a false-negative result (missing a cancer that is present) or a false-positive result (recalling a woman for further workup when cancer is not present).
False positives lead to unnecessary tests, including biopsies.
Women in their 40s tend to have dense breast tissue, making their mammograms hard to interpret. Dense breast tissue shows up as white on a mammogram and can obscure abnormal findings, which are also white.
Breast density varies slightly with menstrual cycle.Dr. Miglioretti's team asked whether mammography conducted at different times in the menstrual cycle, when breast density may be different, is more sensitive for finding breast cancers or more specific for ruling out cancer. They examined 387,218 screening mammograms from premenopausal women. Of these, 1,283 were linked to an actual case of breast cancer. The data were from the Breast Cancer Surveillance Consortium, a network of research sites nationwide—including Group Health Research Institute, which has collected breast cancer screening data since 1994.
"Premenopausal women having regular screening mammography could benefit from scheduling their exams during the first week of their menstrual cycle," says Miglioretti. She and her collaborators found that in the first week, when breast tissue may be less dense and not engorged, mammography was more sensitive at detecting cancer. Specificity, which is the ability to reliably recognize the absence of breast cancer, did not change with menstrual cycle.
Miglioretti notes, however, that the increased sensitivity was only for women with a screen in the past two years, who were assumed to be having regular screens, and not for women being screened for the first time. Miglioretti says this result was "surprising," but offers some possible reasons. In general, when first screens find a tumor, it's relatively large. Low breast density is more important for detecting small tumors, so the menstrual cycle influence might not have been seen for first screens. "Larger tumors may be easier to see later in the menstrual cycle, but this needs to be studied," says Miglioretti. In addition, her findings do not apply to diagnostic mammography: mammography performed to work up a symptom such as a breast lump. If a woman finds a breast lump or has another breast concern, she should contact her doctor right away.
Dr. Miglioretti and her co-authors know that women can't always predict their cycle, but say if they can, scheduling during the first week may have an additional advantage. Many women experience breast tenderness in the second half of their cycle, so avoiding this time could reduce mammography discomfort.
Current recommendations are that women aged 50-74 have a routine screening mammogram every other year. Women are encouraged to consult with their health care providers to find a mammography schedule that fits their family history and personal preferences.
Provided by Group Health Research Institute
Rate this story - 5 /5 (1 vote)Medicine & Health / Psychology & Psychiatry
38 minutes ago | 5 / 5 (1) | 0 |
Researchers have long argued that marriage generally reduces illegal and aggressive behaviors in men. It remained unclear, however, if that association was a function of matrimony itself or whether less "antisocial" men were ...
Medicine & Health / Research
32 minutes ago | not rated yet | 0 |
Researchers at University of Toronto and the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, as well as colleagues in Michigan and Scotland, have developed an innovative computational approach -- the first of ...
Medicine & Health / Cancer
1hour ago | 5 / 5 (1) | 0 |
(PhysOrg.com) -- Women treated for breast cancer who have elevated levels of circulating insulin face substantially higher mortality rates than their peers with lower levels, according to a new study authored by a Yale School ...
Medicine & Health / Psychology & Psychiatry
1hour ago | not rated yet | 0
Mindfulness-based cognitive therapy appears to be similar to maintenance antidepressant medication for preventing relapse or recurrence among patients successfully treated for depression, according to a report in the December ...
Medicine & Health / Psychology & Psychiatry
50 minutes ago | not rated yet | 0
The rate of depression treatment increased between 1998 and 2007 but at a slower rate than during the previous decade, and the percentage of patients treated with psychotherapy continued to decline, according to a report ...
Physics / General Physics 26 minutes ago | 5 / 5 (1) | 0 | (PhysOrg.com) -- Researchers at RIKEN, Japan's flagship research institution, have successfully devised the world’s first experimental technique for measuring ground-state hyperfine transitions of antihydrogen. ... Medicine & Health / Health 30 minutes ago | not rated yet | 0 High blood pressure may help to explain why deaths from heart disease and stroke vary according to geography, race and sex, researchers reported in Hypertension: Journal of the American Heart Association. Medicine & Health / Health 20 minutes ago | not rated yet | 0 Children who attend large group child care facilities before age 2½ appear to develop more respiratory and ear infections at that age, but fewer such illnesses during elementary school years, according to a report in ... Medicine & Health / Psychology & Psychiatry 10 minutes ago | not rated yet | 0 Among patients with depression, the presence of many aspects of illness which may be associated with bipolar disorder does not appear to be associated with treatment resistance—evidence against the common hypothesis ... Medicine & Health / Psychology & Psychiatry 9 minutes ago | not rated yet | 0 People with psychotic disorders, such as schizophrenia or bipolar disorder, are 12 times more likely to commit suicide than average, according to research released today by King's Health Partners. 
Space & Earth / Space Exploration 29 minutes ago | not rated yet | 0 (PhysOrg.com) -- Cosmologists have come up with a new way to solve their problems. They are inviting scientists, including those from totally unrelated fields, to participate in a grand competition. The idea ... Medicine & Health / Psychology & Psychiatry 1 seconds ago | not rated yet | 0 Two toddlers are learning the word "cup." One sees three nearly identical cups; the other sees a tea cup, a sippy cup and a Styrofoam cup. Chances are, the second child will have a better sense of what a cup is and -- according ... 
Medicine & Health / Neuroscience 30 minutes ago | not rated yet | 0 Scientists in Bristol have uncovered some of the processes responsible for the blood flow problems connected with Alzheimer’s disease. Their findings could see existing drugs used for leaky blood vessels ... Medicine & Health / Neuroscience 56 minutes ago | not rated yet | 0 Women with transient restless legs syndrome (RLS) during pregnancy appear to be at a higher risk of developing a chronic form of RLS later in life or have the same symptoms during future pregnancies, according to new research ... 
Other Sciences / Other 2 minutes ago | not rated yet | 0 President Barack Obama urged Monday a refocus on scientific research and teaching, as was triggered by the launch of the Soviet's 1957 Sputnik satellite, saying it was key to future US prosperity, Prevent vitamin E tocotrienols breast cancer to?
Because one eight women from each, to develop breast cancer, an enormous amount of research has made to discover ways to prevent this common killer. Connecting has studied extensively for its role in the prevention of breast cancer is Tocotrieonls vitamin e.
When to check all published evidence, it does not appear that alpha tocopherol vitamin E gives a protective effect against breast cancer. Yet studies show that women consume foods with a high in other forms of vitamin E (tocotrienols) significantly reduce breast cancer (of less than 90%) your risk of the customer.
A cardinal feature of breast tumours are simply cells multiply. Estrogen promote drugs to hyper-proliferation, and this is one reason why these drugs can quadruple the incidence of breast cancer.
Studies of breast cancer cells in culture show that tocotrienols have potent effects in inhibiting proliferation and induction of apoptosis (cancer cell death). These studies show that alpha-tocopherol same not this advantage.
Alpha-tocopherol acetate is the most common form of vitamin E supplement, but the evidence points to other forms of vitamin E as responsible for the dramatic reduction of in breast cancer incidence in large human studies observed.
Each tocopherols and tocotrienols have different biological activities as your impact related to the cellular function. Gamma tocopherol, compared for example demonstrated significant cancer-prevention effects with alpha tocopherol.
The potential cancer effects for the Gamma tocopherol and the tocotrienols deserves aggressive human clinical research to determine if women supplemented with these unique forms of vitamin E may reduce your risk of infection with breast cancer. Further research to see whether the addition of tocotrienols to tamoxifen improves long-term survival rates are carried out on patients with breast cancer.
There is no convincing evidence that vitamin E supplements breast cancer incidence decrease standard (alpha-tocopherol). While alpha tocopherol to protect against a variety of other diseases has shown, it seems that the tocotrienols are the ideal form of vitamin E, specifically to reduce breast cancer risk.
Hovid is the first company in the world, a commercial develop integrated process for extracting valuable carotenoids and tocotrienols scale of palm oil. Experts believe that overall Palm tocotrienols one will be the top governing additions of the new century.
Article articlesbase.com
More breast cancer articles
Tagged as: breast, cancer, prevention, tocotrienols, vitamin
Times staff ReportsPosted: 12/06/2010 12: 00: 00 am the MSTCentro San Vicente, 8061 Alameda was awarded $35,000 in grants for cancer prevention programmes.
The Centre j. Edward and Helen m.c. Star Foundation $10,000 awarded for early detection and treatment costs.
One of the Rio Grande Cancer Foundation $25,000 contract renewed for a second year of support of the Centre's well women's health program. Breast cancer screening and post diagnostic follow-up covering for women members of the program.
Kick-off party is Thursday for El Paso Marathon
El Paso Marathon Foundation will have a kickoff at 5: 30 to 19: 00 Thursday in the garden, 511 Western party.
El Paso Marathon will be March 6. Pre-registration prices are $70 for the full marathon, $50 for a half marathon and $35 for a 5 K run / walk.
Someone has a past year El Paso-Marathon-T-shirt, which affect the kick-off party registered will receive a discount of $5.
Information: elpasomarathon.org.
Blood drives
Franklin high school, 900 N. Resler, is a blood drive from 8 A.m. until 4 P.m. today at the gymnasium of the school have. Voluntary blood donors must be at least 17 years old (or 16 with parent permission), weigh at least 110 pounds, and be in good health. Additional height weight requirements apply to donors 22 and younger.
La Fe is culture and Technology Center have a blood drive from 10 A.m. to 4 P.m. Tuesday in the Middle, 721 S. Ochoa, rear building. 545-7190.
Screenings
We want athletes honor 'everyday'
Do you have a workout routine that has kept fit? The El Paso Times wants to hear from you. Your story can be in our "everyday athlete"-feature appears.
We are looking for average people of all ages who maintain a healthy lifestyle.
Send your story to living@elpasotimes.com in the following format:
Please take a color photo.
Print 
eMail 
font resize 
return to top SAN DIEGO, January 8, 2010 / PRNewswire-FirstCall /-AltheaDx, Inc. - http://www.altheadx.com - announced today the formation of a strategic partnership with compendia Bioscience to combine their respective core competencies in assay development, validation and bioinformatics. The two companies will together create innovative products and services that focuses on cancer biomarker discovery and subsequent development of testing predict patient outcomes in clinical trials. As of 2006 has AltheaDx FFPE of tissue-based biomarkers discovery and companion diagnostic development allows. AltheaDx has facilitated the clinical use of biomarkers through validation and clinical example tests under GLP and/or CLIA.
Compendia Bioscience co-founder and CEO, said Dan Rhodes, "AltheaDx has since its inception with very deep technical skills in genetic analysis a pioneering developer of PCR-based assays in clinical settings." "We are thrilled by this new strategic partnership."
The inaugural launch of the strategic partnership is the breast cancer segregation Panel ™ assay. This test is a real time PCR based, optimized for the analysis of RNA from formalin-fixed, paraffin-embedded (FFPE) tissue extracts. This Panel measures 96 genes in a proprietary meta-analysis of cancer genomic data from more than 5,000 clinical samples to identify. AltheaDx processed and San Diego-based CLIA/GLP laboratory to analyse, to patient during compendia Bioscience downstream data analysis and statistical correlation results in clinical studies succeed samples in your will.
"We are thrilled to announce this new partnership with compendia Bioscience," said François Ferré, co-founder and CEO of AltheaDx. "The recognized leader in cancer genomic data into meaningful information relating to patient outcomes in clinical trials is to translate compendia Bioscience." "The compendia's powerful bioinformatics platform is very valuable content provide to develop predictive checks we can for our pharmaceutical partners."
Under the terms of the partnership, the companies to develop segregation panels for other types of cancer plan. The next assay, colorectal cancer segregation Panel ™, will be released in 2011.
About AltheaDx, Inc.
AltheaDx, a leading San Diego based diagnostic development and testing company, provides clinical biomarker discovery, development and validation services to support researchers worldwide in their efforts to genomic information for the development of novel therapies use the assay. AltheaDx plays to discover a critical role in pharmaceutical and specify validation of biomarkers that can response, predictions and seamless to an efficient commercialization path for the tests on the market. The AltheaDx aims to most to mitigate risk, reduce costs for therapeutic development for pharmaceutical partners.
For more information, visit www.altheadx.com
About compendia Bioscience, Inc.
Compendia Bioscience is dedicated to the application of the global collection of cancer of genomic data to patient care by enabling discovery and development of better cancer diagnosis and treatment of. www.compendiabio.com
Please contact for further information:
Associate Director, corporate development
SOURCE AltheaDx, Inc.
Back to topRELATED LINKS
http://www.altheadx.com
http://www.compendiabio.com
My mother had a mammogram and found a lump. Is 57 and smoke a few months ago. What are the chances its breast cancer ball park %?
Early-stage breast cancer tumors of "unknown cause" may not be unknown after all, according to a University of Pittsburgh study.
Rather, they probably are caused by defects of DNA repair mechanisms that allow environmentally triggered mutations to pile up, according to the study by Pitt of school of medicine, Magee-Womens Hospital of UPMC, and the University of Pittsburgh Cancer Institute.
The study therefore indicates that the potent chemotherapy drugs used to target DNA in later-stage cancers could be an effective treatment for the early-stage tumors.
The findings, reported recently in early online edition of the proceedings of the National Academy of science, grew out of the research team's ability to grow and assess 19 stage I tumors of unknown cause placed into culture directly from surgeries.
In each case there what the environmentally triggered mutations compared to the same a deficiency in the tumor's ability to repair mechanism in healthy breast tissue. Earlier research had shown that the repair process is one-fifth as effective in healthy breast tissue as it is, for example, in skin tissue.
Some examples of such environmental triggers could be certain chemicals released by smoking; the chemical in plastics, Bisphenol A, or BPA. hormone replacement therapy; and various by-products of anything that burns, said lead author Jean Latimer, to assistant professor of obstetrics, gynecology and reproductive sciences in the medical school.
"[The tumors] were all stage I but of different subtypes [before the culturing]," Dr. Latimer said. "They were from women of different ages, women who were post-menopausal women who were pre-menopausal. After the culturing, all 19 tumors showed the deficiency in DNA repair capacity. Normally a complex system of proteins trolls the DNA strands to identify problems and initiate repair processes.
"You don't usually see uniformity in human cancer" Dr. Latimer said of the common DNA repair deficiency. "... "It's remarkable to find large something universally true in a group that."
This finding is particularly important because at estimated 85 percent of the 190.000 breast cancers diagnosed every year are of unknown cause. The other 15 percent can be traced to family history.
"It's telling us about the etiology of 85 percent we haven't understood before," Dr. Latimer said. "It also implicates environmental damage as part of the cause." ...
"So it means we can start thinking about the air we breathe and the water we drink in order to reduce this very common kind of cancer," she added. "It speaks to prevention of breast cancer as a public health issue."
The use of the chemotherapy drugs that target DNA in later-stage tumors would give women with stage I cancers another option or something they could use for treatment with surgery or other therapies.
"We know that with stage I tumors some already have metastasized - we just haven't found the metastasis," said senior author Stephen Grant, to associate professor in the Department of environmental and occupational health at Pitt's Graduate School of public health. "Those that have escaped localized treatment, we can't find right those now." "That's another aspect of our research."
The two researchers said that one of the problems with breast cancer is that it's not homogenous - some is over-treated, some is under-treated. "What our work says is all early-stage sporadic tumors should be susceptible to genotoxic therapy, under the right circumstances," Dr. Grant said.
The Wall Street Journal Business Welcome, Logout My Account My Journal Help Message Center ( new) WSJ.com is available in the following editions and languages:
U.S. Asia India China Japan Europe Americas en Español em Português Register for FREE Register for FREE Thank you for registering.We sent an email to:
Please click on the link inside the email to complete your registration
Please register to gain free access to WSJ tools.
An account already exists for the email address entered.
Forgot your username or password?
This service is temporary unavailable due to system maintenance. Please try again later.
The username entered is already associated with
another account. Please enter a different username
The email address you have entered is already in use.
Please re-enter the email address.
From time to time, we will send you e-mail announcements on new features and special offers from The Wall Street Journal Online.
Create a profile for me in the Journal Community
Why Register? Privacy Policy | Terms & ConditionsAs a registered user of The Wall Street Journal Online, you will be able to:
Setup and manage your portfolio
Personalize your own news page
Receive and manage newsletters
Login/Register to set your edition Today's Paper Video Blogs Journal Community Log In Log In Login Password Log in Your login is either a username or an email address.Keep me logged in. Forgot your password?
More Industries 
Accounting Advertising Airlines Banking Chemicals Computer Hardware Computer Software Consumer Products Defense & Aerospace Broadcasting & Entertainment Financial Services & Insurance Food & Tobacco Hospitality Industrial Goods & Services Media Agencies Paper & Forest Products Pharmaceutical & Biotech Real Estate Retail Semiconductors Transportation 
CloseDow Jones Reprints: This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers, use the Order Reprints tool at the bottom of any article or visitwww.djreprints.com
See a sample reprint in PDF format.Order a reprint of this article now
ZURICH (Dow Jones)--Roche Holding AG (ROG.VX), the world's biggest maker of oncology drugs, risks losing more than 1 billion Swiss francs ($1 billion) in sales next year if U.S. and EU regulators decide to revoke top-selling Avastin's license to treat breast cancer patients.
Analysts expect the sales drop to be between CHF500 million and CHF1.5 billion, depending on how harsh regulators will curtail the drug's use. The larger figure would represent a 25% decline for Avastin, which is used for treating lung, kidney, colorectal and breast cancer. It is Roche's best-selling medicine, contributing more than 10% to overall sales of ...
Email 
Printer Friendly 
Order Reprints Share: 
Digg
StumbleUpon
Viadeo
Orkut
Yahoo! Buzz
Fark
del.icio.us
MySpace
Copyright 2010 Dow Jones & Company, Inc. All Rights Reserved
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit
www.djreprints.com
Back To Back ToMSN Money HomepageMSN Money InvestingMost Popular ReadEmailedVideoCommentedSearches1.Consumer Reports Thumps AT&T 2.Obama Woos Wary Party on Tax Deal3.Opinion: Best of the Web Today: Birther of The Nation4.Hackers Strike Back to Support WikiLeaks5.Opinion: Obamanomics Takes a Holiday1.A Device to Kill Cancer, Lift Revenue2.New Rules for Food Allergies3.Consumer Reports Thumps AT&T 4.Baby May Be Giving You Mommy Thumb5.Hollywood's Guide to the Bowl Games1.Why Luxury Car Buyers May Expect a Wait2.AM Report: Obama Faces Liberal Critics of Tax Deal3.The New Men's Club: Urology Radiation Centers4.And the Loo of the Year Award Goes to...5.Opinion Journal: A Good Tax Deal?1.Deal Struck on Tax Package960 comments2.Obama Woos Wary Party on Tax Deal646 comments3.Tax Deal Within Reach455 comments4.China Clones, Sells Russian Fighter Jets383 comments5.Opinion: Prosecute Assange Under the Espionage Act296 comments 1. Facebook 2. economy 3. Apple 4. Mad Men 5. China Most Read Articles Feed Most Emailed Feed Most Popular Video Feed Most Commented FeedMost Popular Feeds Editors' Picks![[1207edwards]](/OB-LF1921207edC20101207165522.jpg)
Feisty Campaigner Drew Sympathy Amid Tragedy![[OB-LE959_heidi_C_20101207110231.jpg]](/OB-LE959heidiC20101207110231.jpg)
Why Narcissism Defines Our Time![[OB-LE701_1206ny_C_20101206181236.jpg]](/OB-LE7011206nyC20101206181236.jpg)
Big Bear Jackpot: Q&A With New Jersey Hunter![[1208WORKFAM02]](/OB-LF1011208WOC20101207133017.jpg)
Cramming More Into 24 Hours![[OB-LF581_r2_C_20101208093122.jpg]](/OB-LF581r2C20101208093122.jpg)
GM To Demonstrate Space Robonaut 'R2' (Video)![[OB-LF579_120810_C_20101208092116.jpg]](/OB-LF579120810C20101208092116.jpg)
Albert Haynesworth: 335 Pounds of Drama![[OB-LE860_1207mi_C_20101207023215.jpg]](/OB-LE8601207miC20101207023215.jpg)
Can a Michelin Star Boost Business?![[LionBottom]](/P1-AY540LionBoC20101207190658.jpg)
'Birds' Book Soars to Record Sale![[MCCOURT_SUB]](/NA-BJ326MCCOURC20101207191915.jpg)
Judge's Call Divides Dodgers![[BENEFITS]](/NA-BJ297BENEFIC20101206182451.jpg)
Same-Sex Benefits Ban Roils El Paso![[shoah]](/ED-AM684shoahC20101207160916.jpg)
Epic History of the Holocaust Returns![[teach]](/ED-AM683teachC20101207160810.jpg)
Nurturing Creativity in the Next Generation![[OB-LE903_1207wi_C_20101207041550.jpg]](/OB-LE9031207wiC20101207041550.jpg)
Wine 101: Old World vs. New![[OB-LE901_prius_C_20101207040812.jpg]](/OB-LE901priusC20101207040812.jpg)
Toyota's Prius to Become Top Japan Seller — Ever![[OB-LE946_Whiteb_C_20101207100320.jpg]](/OB-LE946WhitebC20101207100320.jpg)
Walking Away from Your Home for Dummies![[OB-LE941_120710_C_20101207083804.jpg]](/OB-LE941120710C20101207083804.jpg)
What to Do With an Orphaned Franchise?Videoprevious nextOpinion Journal Opinion Journal: Hunting Assange4:15Opinion Journal Opinion Journal: A Good Tax Deal?9:42Opinion Journal Opinion Journal: Dodging Hillary3:46Opinion Journal Opinion Journal: Washington's Tax Deal8:35Opinion Journal Opinion Journal: Worst Job Market in Decades8:18Opinion Journal Opinion Journal: The FDA Power Grab5:44Opinion Journal WikiLeaks R Us2:34Opinion Journal Opinion Journal: Who Will Run Congress?2:25Opinion Journal Opinion Journal: Democrats Get Nervous7:08Opinion Journal Opinion Journal: The Haitian Elections 4:46Opinion Journal Opinion Journal: WikiLeaked8:36Opinion Journal Opinion Journal: How WSJ Creates Its Op-Ed Page6:27Opinion Journal Opinion Journal: Corruption in India2:57Opinion Journal Opinion Journal: Think TSA is Bad Now?6:21Opinion Journal Opinion Journal: Guide to Insider Trading4:47 Most Recommended CommentsComments CommentersCommenters 1. “
Peter Venetoklis 852 Recommendations 
jean balloon 655 Recommendations 
Greg Liautaud 519 Recommendations 
Eric Nelson 510 Recommendations Jonathan Murray 505 Recommendations Most Active Discussions Journal Community 
Question of the Day Should Congress pass a plan which extends tax cuts for all Americans, lowers payroll taxes for 2011 and extends unemployment benefits?
The Obama Administration Should the Bush-era tax cuts for all income levels be extended?
Libertarians What do you think about Kyle Townsend’s libertarian social structure?
Libertarians Is a Libertarian Society a Pipedream?
Question of the Day Would you use an Internet “do-not-track” tool if it were included in your Web browser?
See all Discussion Groups More in BusinessOverhaul of Oil Industry UrgedNew Faces, Ties in Trading ProbeKFC Savors Potential in AfricaInvestors Pile Into CommoditiesFortune Brands Plans to Split Up
null Email Newsletters and AlertsThe latest news and analysis delivered to your in-box. Check the boxes below to sign up.
WSJ.com Email Features Real Time Economics Newsletter News AlertSubmit The email address null is already associated with another account. Please enter a different email address: Enter Your EmailThank you !
You will receive in your inbox.
The latest news and analysis delivered to your in-box. Check the boxes below to sign up.
WSJ.com Email Features This Week's Most Popular On the Editorial PageSubmit The email address null is already associated with another account. Please enter a different email address: Enter Your EmailThank you !
You will receive in your inbox.
Feisty Campaigner Drew Sympathy Amid TragedyWhy Narcissism Defines Our TimeBig Bear Jackpot: Q&A With New Jersey HunterCramming More Into 24 HoursGM To Demonstrate Space Robonaut 'R2' (Video)Albert Haynesworth: 335 Pounds of DramaCan a Michelin Star Boost Business?'Birds' Book Soars to Record SaleJudge's Call Divides DodgersSame-Sex Benefits Ban Roils El PasoEpic History of the Holocaust ReturnsNurturing Creativity in the Next GenerationWine 101: Old World vs. NewToyota's Prius to Become Top Japan Seller — EverWalking Away from Your Home for DummiesWhat to Do With an Orphaned Franchise? WSJ Web Slice CONTENT LINKS TO ACTUAL PAGE CONTAINING WEB SLICE FUNCTIONALITY. 15back to top WSJ.com Account:My AccountSubscriber Billing InfoCreate an Account:Register for FreeSubscribe to WSJ.comSign up for WSJ ProfessionalHelp & Information Center:HelpCustomer ServiceContact UsNew on WSJ.comTour the new JournalAbout:News LicensingAdvertisingAdvertise LocallyConferencesAbout Dow JonesPrivacy Policy - UpdatedSubscriber Agreement & Terms of Use - UpdatedCopyright PolicyJobs at WSJ.comFuture Leadership ProgramWSJ.com:Site MapHomeWorldU.S.New YorkBusinessMarketsMarket DataTechPersonal FinanceLife & CultureOpinionAutosCareersReal EstateSmall BusinessStudent JournalCorrectionsTools & Formats:Today's PaperVideo CenterGraphicsColumnsBlogsTopicsGuidesAlertsNewslettersMobileTablet EditionPodcastsRSS FeedsJournal Community- Message CenterWSJ on TwitterWSJ on FacebookWSJ on FoursquareMy JournalPortfolio
Digital NetworkWSJ.comMarketwatch.comBarrons.comSmartMoney.comAllThingsD.comFINS: Finance, IT jobs, Sales jobsBigCharts.comVirtual Stock ExchangeWSJ RadioProfessorJournal.comWSJ U.S. EditionWSJ Asia EditionWSJ Europe EditionWSJ India PageForeign language editions:WSJ ChineseWSJ JapaneseWSJ PortugueseWSJ SpanishACAP EnabledCopyright ©2010 Dow Jones & Company, Inc. All Rights Reserved